서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 18 of 18

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-10
ENHANCEMENT OF SORAFENIB SENSITIVITY VIA AKT DOWN-REGULATION BY PROTEIN DISULFIDE ISOMERASE INHIBITION OR PTEN ACTIVATION
2012-02
Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition
DOI
2012-02
Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition.
DOI
2012-03
Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B
DOI
2012-03
Risk Factors, Clinical Features, and Prognosis of the Hepatocellular Carcinoma with Peritoneal Metastasis

Kwak, Min-Sun; Lee, Jeong-Hoon; Yoon, Jung-Hwan; Yu, Su Jong; Cho, Eun Ju; Jang, Eun Sun; Kim, Yoon Jun; Lee, Hyo-Suk

DIGESTIVE DISEASES AND SCIENCES Vol.57 No.3, pp. 813-819

DOI
2012-03
Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B
DOI
2016-11
TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
DOI
2018-03
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study
view fileDOI
2018-12
Analysis of significant protein abundance from multiple reaction-monitoring data
view fileDOI
2019-05
Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data
view fileDOI
2020-10
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
view fileDOI
2021-02
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
DOI
2022-01
Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation
DOI
2022-02
Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults
DOI
2022-05
The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study
DOI
2022-07
Correlation between Results of Semi-Quantitative and Quantitative Tests for Hepatitis B Virus Surface Antigen among Patients Achieving Viral Suppression with Antiviral Treatment
DOI
2022-12
The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
view filelink
2023-10
A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma
view fileDOI
1